Merus NV (MRUS) Given Consensus Rating of “Hold” by Analysts
Merus NV (NASDAQ:MRUS) has been given an average rating of “Hold” by the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $30.25.
MRUS has been the subject of a number of recent analyst reports. Royal Bank of Canada reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Merus in a research note on Wednesday, October 18th. Jefferies Group reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Merus in a research note on Thursday, October 26th. Wedbush reaffirmed an “outperform” rating and issued a $32.00 price objective on shares of Merus in a research note on Friday, January 12th. Zacks Investment Research raised Merus from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Finally, BidaskClub raised Merus from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 30th.
Merus (NASDAQ:MRUS) opened at $16.27 on Friday. The firm has a market capitalization of $309.73 and a PE ratio of -2.34. Merus has a one year low of $13.23 and a one year high of $33.63.
ILLEGAL ACTIVITY WARNING: “Merus NV (MRUS) Given Consensus Rating of “Hold” by Analysts” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://theolympiareport.com/2018/02/11/merus-nv-mrus-given-consensus-rating-of-hold-by-analysts.html.
Merus Company Profile
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.